Communiqués MEI Pharma, Inc. Börse Stuttgart

Actions

MMI0

US55279B3015

Temps Différé Börse Stuttgart Autres places de cotation 16:55:57 14/04/2023			Varia. 5j.	Varia. 1 janv.
4,272 ^EUR	+0,38 %		+1 961,78 %	+1 757,39 %

09/05	MEI Pharma, Inc. annonce ses résultats pour le troisième trimestre et les neuf mois terminés le 31 mars 2024	CI
11/04	MEI Pharma, Inc. annonce un plan stratégique visant à exploiter les récentes données cliniques positives sur le voruciclib et le ME-344	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	14/05	BU
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights	09/05	BU
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab in Relapsed Metastatic Colorectal Cancer Patients	12/04	AQ
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	11/04	BU
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344	11/04	BU
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum	10/04	BU
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	26/03	BU
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	15/02	BU
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights	13/02	BU
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024	16/01	BU
MEI Pharma : Change in Certifying Accountants - Form 8-K	26/12	PU
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	14/12	BU
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023	11/12	BU
MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights	09/11	BU
MEI Pharma to Present at the Stifel 2023 Healthcare Conference	08/11	BU
MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock	06/11	BU
MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023	02/11	BU
MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital	01/11	BU
MEI Pharma Recommends Stockholders Not to Consent	17/10/23	BU
MEI Pharma Adopts Limited-Duration Stockholder Rights Plan	02/10/23	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués MEI Pharma, Inc. Börse Stuttgart

Actions

MMI0

US55279B3015

Communiqués

Filtres